Recruiting

Hematopoietic Cell Transplantation

Sponsor:

Center for International Blood and Marrow Transplant Research

Code:

NCT04920474

Conditions

Autologous Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

Cellular Therapy

Marrow Toxic Injury

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The primary purpose of the Research Sample Repository is to make blood samples available for research studies related to histocompatibility and hematopoietic cell transplantation (HCT) or other cellular therapy.

Representatives of participating centers and investigators or research groups may request access to research samples contained in the Research Sample Repository for the purpose of conducting research including:

  • investigating molecular explanations for histocompatibility or clinical outcomes through analysis of genomic, epigenetic, or other biomolecular data
  • evaluating the factors that affect transplant or cellular therapy outcome
  • studying the distribution of HLA tissue types in different populations
  • studying the success of transplantation, cellular therapies or supportive care in the management of marrow toxic injuries
  • performing de-linked (anonymous) research

Conditions

Autologous Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

Cellular Therapy

Marrow Toxic Injury

Study ID

NCT04920474

Start date

Jul, 1991

Status verified date

Mar, 2023

Completion date

Jul, 2030

Anticipated

Primary completion date

Jul, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Eligibility to participate in the Research Sample Repository Protocol:

Hematopoietic Cell (HC) or Other Cellular Therapy Donors

  • Donors are eligible to participate in the Research Sample Repository if they have donated or are scheduled to donate HCs or cellular therapy products to an allogeneic recipient either by a marrow harvest or by apheresis. This includes adults with and without decision making capacity and children.
  • All donors registered on the National Marrow Donor Program (NMDP) Registry, regardless of whether they have been requested to donate a product for a patient, are eligible to participate in the Research Sample Repository.

Cord Blood Units (CBUs)

  • Testable material from CBUs (Specimens) infused at treatment centers covered under the C. W. Bill Young Transplantation Program are eligible for inclusion in the Research Sample Repository. Material may be submitted by participating treatment centers, centralized laboratories and Cord Blood Banks.

Hematopoietic Cell Transplantation or Other Cellular Therapy Recipients

  • All U.S. recipients of allogeneic or autologous HC transplants or cellular therapies are eligible to participate in the Research Sample Repository. This includes adults with and without decision making capacity and children.

Patients with Marrow Toxic Injury

  • Any patient who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Treatment Network (RITN) is eligible to participate in the Research Sample Repository. This includes adults with and without decision-making capacity and children.
  • Eligible patients may have received support care only, growth factor support, hematopoietic stem cell transplant or other appropriate medical treatment for marrow toxic injury

Study Design

Enrollment

99999999 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • To make blood samples available for research studies related to histocompatibility and HCT or other cellular therapy [ Time Frame: pre-HCT (recipient) or pre-donation (donor) ]

Central Contacts and Locations

Central contacts

Ashley Spahn

RepositoryIRB@NMDP.ORG

Locations

NMDP Biorepository

Recruiting

New Brighton, Minnesota, United States, 55112

Contacts

Liz Weideman

651-745-5036ewiedenm@nmdp.org

More Information

Sponsor

Center for International Blood and Marrow Transplant Research

Last update posted

May 3, 2023

Last verified

Mar, 2023

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Center for International Blood and Marrow Transplant Research on 2023-05-03.